Morphologic Characteristics of Myelodysplastic Syndromes
Journal Title:
Clinics in Laboratory Medicine
Original Publication Date:
Dec 2023
Bone Marrow Disease(s):
Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired hematological disease. The development of complement inhibitors such as eculizumab, ravulizumab, and pegcetacoplan has revolutionized the management of PNH, leading to improvements in overall survival and quality of life for patients.